CARM missed EPS expectations by 79.74%
May 15, 2025, 10:34 PM
0.00%
What does CARM do
Carisma Therapeutics, a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focuses on developing immunotherapies for solid tumors, including CAR-M therapies CT-0508 and CT-0525. The company went public in February 2014 and employs 107 people.
Carisma Therapeutics (CARM) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Carisma Therapeutics's actual EPS was -$0.22, missing the estimate of -$0.12 per share, resulting in a -79.74% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.